Comparing CAR T-Cell Therapies for LBCL: Insights From CART-SIE Study
December 12th 2024Real-world study compares the efficacy and safety of axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel), finding that axi-cel provides superior progression-free survival but with higher toxicity.
Read More
Characteristics of Accountable Care Organizations’ Preferred Skilled Nursing Facility Networks
December 12th 2024Medicare accountable care organizations use preferred skilled nursing facility networks for postacute care management, although the size, structure, and resource allocation of networks vary widely.
Read More
In Myeloid Neoplasms, Next-Generation Sequencing Can Be Inappropriate—and Money-Wasting
December 12th 2024A Yale School of Medicine team has created lists of criteria to help clinicians determine when next-generation sequencing (NGS) is appropriate for a patient with a myeloid neoplasm (MN), and when it is not.
Read More
Elacestrant Shows Real-World Effectiveness in Metastatic Breast Cancers
December 11th 2024Patients with ER-positive/HER2-negative metastatic breast cancer who received elacestrant experienced a significant reduction in disease progression or death compared with standard-of-care endocrine therapy.
Read More
ASH 2024 Showcases Real-World Data Demonstrating Efficacy of Ruxolitinib Across Multiple Conditions
December 10th 2024Two posters presented at the 2024 American Society of Hematology meeting bolster evidence supporting the long-term clinical benefits of ruxolitinib for polycythemia vera and chronic graft-vs-host disease.
Read More
An Integrated Practice Unit Tool for the Military Health System
Researchers developed and tested an assessment tool to measure coordinated care for traumatic brain injury against the criteria of an integrated practice unit.
Read More
6-Year Data Support Fixed-Duration Ven-Obi for Untreated CLL
December 10th 2024Long-term data support the safety and efficacy of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL), though questions remain about which patients would benefit most from the regimen.
Read More
Nanoparticle Delivery Holds Promise for Treatment of PAH
December 8th 2024Aerosolized vascular endothelial growth factor/stromal cell-derived factor-1α (VEGFNP/SDFNP) led to a lower pulmonary arterial pressure and prevented right ventricular hypertrophy after monocrotaline (MCT) injection in rats.
Read More
Clinical Features Vary Across Myasthenia Gravis Foundation Classes
December 7th 2024Myasthenia Gravis Foundation of America (MGFA) class correlates with activities of daily living and other clinical characteristics on a group level, but individual variability is significant between patients of the same MGFA class.
Read More
New Data Reinforce Iptacopan's Role in Transforming PNH Care With Hemoglobin, QOL Gains
December 6th 2024Promising topline results from a phase 3B study show the efficacy and quality of life (QOL) improvements of iptacopan (Fabhalta) as a twice-daily oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who transitioned from anti-C5 therapies.
Read More
Slow, Steady Advances: Noninvasive Diagnosis of PH in ILD Populations
December 5th 2024Many roadblocks exist to detecting and assessing pulmonary hypertension (PH) in patients with interstitial lung disease (ILD), but creative thinking and artificial intelligence (AI) may soon help improve the landscape.
Read More
The Silver Lining: Progress and Promise in Combating STIs
Published: December 3rd 2024 | Updated: December 4th 2024With new CDC data expressing optimism about the epidemic of sexually transmitted infections (STIs), take a look at the current novel approaches in STI care and learn about crucial next steps to combat this public health issue.
Read More
Advent of Ponatinib for Ph+ ALL Expected to Influence New Guidelines
November 29th 2024With ponatinib (Iclusig) receiving an accelerated approval from the FDA earlier this year for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), updated guidelines could be on the horizon.
Read More
US ADHD Stimulant Shortage Highlights Growing Challenges in Adult Treatment
November 27th 2024While name brands like Adderall and Vyvanse may have been recently removed from the FDA Drug Shortage Database, it's unclear if it'll last; meanwhile, many generic forms of attention-deficit/hyperactivity disorder (ADHD) medication are still in short supply.
Read More